News | September 30, 2013

Average Phase I Trial Costs Approach $9,000 Per Patient Per Month

Neurology trials cost the most at $8,943 per patient per month, found Cutting Edge Information

September 30, 2013—A study by Cutting Edge Information found that pharmaceutical companies measure cost per patient per month to allow trials of different sizes and durations to be compared easily. This measurement also helps to illustrate the high costs associated with delays.

The study, “Phase I Clinical Trials: Optimizing Cost-Drivers for Clinical Pharmacology Programs,” found that neurology and central nervous system (CNS) trials cost the most at $8,943 per patient per month. The trials’ high price tag, combined with a relatively short average duration of 9.6 months helps CNS top the list among all surveyed therapeutic areas.

Surveyed cardiology and respiratory Phase I trials’ short average durations (8.6 months and 5 months, respectively) help to elevate these therapeutic areas above oncology in terms of cost per patient per month. In fact, oncology trials’ relatively average long duration (36 months) gives the therapeutic area an average cost per patient per month of $2,822.

The research team at Cutting Edge Information analyzed cost per patient per month data for oncology, cardiology, CNS and gastroenterology trials. The following are highlights from each therapeutic area:

  • An oncology trial reported the second highest cost per patient per month ($20,635) of all trials in this study behind only one CNS trial.
  • A cardiology trial, which incurred the lowest cost per patient per month at $2,375, lasted five months longer than the other trials studied. This is a rare instance when shorter trials incur higher total costs — likely the result of imaging procedures built into their protocol.
  • CNS trials have the widest range of costs per patient per month at $20,606.
  • Gastroenterology trials report the narrowest range of cost per patient per visit — only $347.
  • “Phase I Clinical Trials: Optimizing Cost-Drivers for Clinical Pharmacology Programs,” (http://www.cuttingedgeinfo.com/research/clinical-development/phase-i-cli...) examines the critical cost drivers when budgeting for Phase I trials. Use this report to:
  • Manage critical cost-drivers when budgeting for Phase I trials.
  • Save time and prevent costly delays with early strategic planning.
  • Balance the number and quality of trial sites during site selection to manage patient enrollment and drop-off rates.

For more information: http://www.cuttingedgeinfo.com/research/clinical-development/phase-i-cli...

Related Content

Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index

Fig. 1: Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index. (Agarwal et al, Red Journal, 2019) Credit: Elsevier

News | Radiation Therapy | April 22, 2019
April 22, 2019 — A new study finds wide state
Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening
News | Colonoscopy Systems | April 15, 2019
Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through...
Deep Lens Closes Series A Financing for Digital AI Pathology Platform
News | Digital Pathology | April 09, 2019
Digital pathology company Deep Lens Inc. announced the closing of a $14 million Series A financing that will further...
Uterine Fibroid Embolization Safer and as Effective as Surgical Treatment
News | Interventional Radiology | April 05, 2019
Uterine fibroid embolization (UFE) effectively treats uterine fibroids with fewer post-procedure complications compared...
News | Biopsy Systems | March 29, 2019
Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy...
Artificial Intelligence Can Improve Emergency X-ray Identification of Pacemakers
News | X-Ray | March 29, 2019
A research team from Imperial College London believes a new software could speed up the diagnosis and treatment of...
Interventional Radiology Treatment for Tennis Elbow Reduces Pain and Inflammation

Image courtesy of Yuji Okuno

News | Interventional Radiology | March 29, 2019
Tennis elbow, a painful chronic condition that affects up to 3 percent of U.S. adults, can be effectively treated...